Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 4354Neoplasms 3055Prostatic Neoplasms 1904Colorectal Neoplasms 1738Lung Neoplasms 1555Carcinoma, Non-Small-Cell Lung 1270Pancreatic Neoplasms 981Multiple Myeloma 951Leukemia, Myeloid, Acute 951Lymphoma 912Head and Neck Neoplasms 894Leukemia 852Precursor Cell Lymphoblastic Leukemia-Lymphoma 833Neoplasm Metastasis 793Colonic Neoplasms 785Carcinoma, Hepatocellular 762Ovarian Neoplasms 757Melanoma 752Stomach Neoplasms 740Rectal Neoplasms 701Brain Neoplasms 696Lymphoma, Non-Hodgkin 663Leukemia, Lymphocytic, Chronic, B-Cell 618Uterine Cervical Neoplasms 607Lymphoma, Follicular 559Glioblastoma 541Recurrence 539Hodgkin Disease 532Esophageal Neoplasms 527Myelodysplastic Syndromes 508

Interventions

Adalimumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × OTHER × Mucopolysaccharidoses × Clear all
NCT02437253 2017-09-15

Effects of Adalimumab in Mucopolysaccharidosis Types I, II and VI

Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

Phase 1/2 Completed
2 enrolled 10 charts

Inflammation, Mucopolysaccharidosis I, Mucopolysaccharidoses, Mucopolysaccharidosis VI, Mucopolysaccharidosis II

Data powered by HemOnc (CC BY 4.0) Colophon âš¡